Essential thrombocythemia
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Essential thrombocythemia. This is a myeloproliferative neoplasm. It may result from the acquired JAK2V617F mutation. Fully referenced neurology checklist.
Pathology
- This is a myeloproliferative neoplasm
- It may result from the acquired JAK2V617F mutation
- It results from an expansion of the megakaryocytic lineage
- This manifests as isolated increase in platelet counts
Systemic features
Locked: subscribe to see this section.
Haemorrhagic features
Locked: subscribe to see this section.
Vascular features
Locked: subscribe to see this section.
Transient neurological features
Locked: subscribe to see this section.
Risk factors for neurological involvement
Locked: subscribe to see this section.
Treatment
Locked: subscribe to see this section.
References
- Billot S, Kouroupi EG, Le Guilloux J, et al. Neurological disorders in essential thrombocythemia. Haematologica 2011; 96:1866-1869.
- Koudstaal PJ, Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Hemost 1997; 23:365-370.
- Martin EA, Lavin PJ, Thompson AJ. Painful extremities and neurological disorder in essential thrombocythaemia. J R Soc Med 1984; 77:372-374.
- Brière JB. Essential thrombocythemia. Orphanet J Rare Dis 2007; 2:3.
- Kato Y, Hayashi T, Sehara Y, et al. Ischemic stroke with essential thrombocythemia: a case series. J Stroke Cerebrovasc Dis 2015; 24:890-893.
- And 8 more. Subscribe to see the full list
